TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8052880
Drug: Conventional RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional RT plus carboplatin 70 mg/m2/d on days 1 to 5 during treatment weeks 1 and 5
Study: 8052880
Drug: Accelerated RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated RT plus carboplatin 70 mg/m2/d on days 1 to 5 of week 1 only
Study: 2564724
Drug: Propranolol, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 80 mg twice daily
Study: 2564724
Drug: Dilevalol, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol, 400 mg once daily
Study: 16703602
Drug: Direct treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct treatment of PTSD
Study: 15210047
Drug: 400 micro
Normalized name: EM 2400 Micro Volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micro g of misoprostol vaginally 6 h before dilatation and curettage
Study: 11280890
Drug: Once a
Normalized name: Once A Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day administration of terazosin (2 mg)
Study: 11280890
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a day administration of terazosin (2 mg)
Study: 9248765
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (4 mg)
Study: 9248765
Drug: Medroxyprogesterone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone (40 mg)
Study: 17126768
Drug: Lactobacillus fermentum
Normalized name: Lactobacillus Fermentum
DrugBank: Lactobacillus fermentum (DB16542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus fermentum 2 capsules twice daily (2 x 10^9 CFU per capsule) for 10 weeks
Study: 9850033
Drug: Lenograstim 2
Normalized name: lenograstim 263 MCG/mL Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim 2 microg/kg daily
Study: 9850033
Drug: Lenograstim 5
Normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim 5 microg/kg daily
Study: 7826820
Drug: Nebivolol with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol with L-NMMA infusion
Study: 3400680
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose regimen: 5 g mezlocillin plus 2 g cefoperazone intravenously every four hours
Study: 3400680
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose regimen: 3 g mezlocillin plus 1 g cefoperazone intravenously every four hours
Study: 3400680
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose regimen
Study: 28844431
Drug: CC (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (usual community care)
Study: 25769911
Drug: BI 655066
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655066 (any dose)
Study: 12751880
Drug: School-based preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based preventive intervention (Botvin, G. J. 1996, 2000)
Study: 8447207
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution before surgery and Ringer‐acetate during surgery
Study: 20628312
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of hypertonic saline-epinephrine (HSE) solution (1 mL) 1 to 2-cm oral to the papilla
Study: 20628312
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (noninjection group)
Study: 17938425
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 on day 1 plus gemcitabine 1 gm/m2 on days 1 and 8 (arm A)
Study: 17938425
Drug: Carboplatin at
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin at AUC of 6 mg on day 1 plus gemcitabine 1 gm/m2 on days 1 and 8 (arm B)
Study: 17002741
Drug: Post-operative oral
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative oral care including tooth brushing, denture cleaning, and tongue cleaning
Study: 17002741
Drug: Post-operative oral
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative oral care
Study: 1425524
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 76 mumol (5 mg) Zn/kg diet
Study: 1425524
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 153 mumol (10 mg) Zn/kg diet
Study: 30900659
Drug: Xylitol chewing
Normalized name: xylitol Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol chewing gum (1.1 g each, 2 pieces daily for 14 days)
Study: 30900659
Drug: Sorbitol chewing
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol chewing gum (1.1 g each, 2 pieces daily for 14 days)
Study: 18691988
Drug: aranidipine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: aranidipine 5 mg
Study: 18691988
Drug: aranidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aranidipine 10 mg
Study: 18691988
Drug: aranidipine 20
Normalized name: lercanidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aranidipine 20 mg
Study: 18691988
Drug: aranidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aranidipine 10 mg (multiple doses)
Study: 18691988
Drug: M-1 metabolite
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-1 metabolite (aranidipine 10 mg)
Study: 18691988
Drug: M-1 metabolite
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-1 metabolite (aranidipine 5 mg)
Study: 18691988
Drug: M-1 metabolite
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-1 metabolite (aranidipine 20 mg)
Study: 15673502
Drug: Newer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer treatment strategies
Study: 772827
Drug: Penicillin 50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin 50,000 U/kg/d and Kanamycin 10 mg/kg/d
Study: 26332338
Drug: Wii-based Movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wii-based Movement Therapy
Study: 26332338
Drug: modified Constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified Constraint-induced Movement Therapy
Study: 23645374
Drug: PureVision SH
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PureVision SH lenses with Alcon Opti‐Free Express solution
Study: 23645374
Drug: PureVision SH
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PureVision SH lenses with Renu Fresh solution
Study: 21590284
Drug: Methylphenidate (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10, 20, and 40 mg)
Study: 8444070
Drug: Metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (400 mg twice a day)
Study: 8444070
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug regimen)
Study: 17578359
Drug: Monsel's solution
Normalized name: Monsel's solution
DrugBank: Ferric subsulfate (DB13885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monsel's solution
Study: 21174751
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment combined with hyperbaric oxygen therapy (HBOT) for two weeks
Study: 21174751
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment alone for two weeks
Study: 21174751
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment combined with HBOT
Study: 19012813
Drug: Triple-bead mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-bead mixed amphetamine salts (starting dose 12.5 mg)
Study: 15869337
Drug: Empirically supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirically supported treatments
Study: 10635188
Drug: Implant supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant supported FPDs (two implants)
Study: 10635188
Drug: Tooth-implant supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth-implant supported FPDs (one implant and one tooth)
Study: 1758244
Drug: Clonidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (1 ml, 0.15 mg) with 3 ml 0.5% hyperbaric bupivacaine
Study: 1758244
Drug: Saline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (3 ml 0.5% hyperbaric bupivacaine plus 1 ml normal saline)
Study: 25661270
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus conventional analgesic treatment
Study: 25661270
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative analgesic treatment
Study: 23399382
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (14 mg for smokers, 7 mg for non-smokers)
Study: 8610716
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (500 micrograms) + albuterol (2.5 mg)
Study: 8610716
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + albuterol (2.5 mg)
Study: 1826567
Drug: Low-dose intradermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intradermal recombinant-derived hepatitis B vaccine (1.0 or 1.5 microgram)
Study: 1826567
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular dose of hepatitis B vaccine
Study: 7080491
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bemetizide, 20 mg triamterene, 20 mg dihydralazine and 20 mg bupranolol (multiple dose regimen)
Study: 7080491
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bemetizide, 20 mg triamterene, 20 mg dihydralazine and 20 mg bupranolol (single dose regimen)
Study: 28120351
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus applied twice daily for 3 weeks
Study: 28120351
Drug: Topical clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clotrimazole applied twice daily for 3 weeks
Study: 21804410
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with open reduction and internal fixation using an angular stable plate and cerclages, with physical therapy starting on the third postoperative day.
Study: 21804410
Drug: Conservative closed
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative closed treatment including closed reduction if displacement exceeded 50% of the diaphyseal diameter, with physical therapy starting on the fifteenth postoperative day.
Study: 9650546
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 650 mg with codeine 60 mg
Study: 2711990
Drug: Nicardipine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 10 mg administered 3 times daily
Study: 2711990
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg administered 3 times daily
Study: 2711990
Drug: Nicardipine 30
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 30 mg administered 3 times daily
Study: 2751476
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg twice daily)
Study: 31474339
Drug: Detomidine gel
Normalized name: detomidine Oral Gel
DrugBank: Detomidine (DB11556)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine gel (40 μg kg‐1) intravaginally (treatment IVG)
Study: 31474339
Drug: Detomidine hydrochloride
Normalized name: Detomidine Hydrochloride
DrugBank: Detomidine (DB11556)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine hydrochloride (10 μg kg‐1) intravenously (treatment IV)
Study: 28462683
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy plus intensive medical therapy
Study: 28462683
Drug: Carotid stenting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid stenting plus intensive medical therapy
Study: 21872138
Drug: Nebivolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (10 mg/d)
Study: 15184276
Drug: Carvedilol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (50 mg/d)
Study: 7637536
Drug: Glycerol ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol ingestion (2.9 to 3.1 g/kg/d) with large volume of fluid (39.2 or 51.1 ml/kg/d)
Study: 576817
Drug: Standard tablet
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tablet formulation (5 mg)
Study: 576817
Drug: Sustained-release capsule
Normalized name: Dilacor 240mg Sustained-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release capsule formulation (20 mg)
Study: 30522504
Drug: Thread-embedding acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thread-embedding acupuncture (TEA) with polydioxanone thread at 14 fixed acupoints, treatment once a week for 4 sessions
Study: 30522504
Drug: Sham TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham TEA with a sham device (thread removed), treatment once a week for 4 sessions
Study: 27400005
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral sildenafil citrate every 8 hours
Study: 23431960
Drug: Cylindrical implants
Normalized name: Imperata cylindrica root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylindrical implants (Group A)
Study: 23431960
Drug: Conical/cylindrical implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical/cylindrical implants (Group B)
Study: 15590859
Drug: Both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implant types
Study: 22005217
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg IV plus dexamethasone 8 mg IV on day 1
Study: 22005217
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg IV plus dexamethasone 8 mg IV on day 1 followed by oral dexamethasone 8 mg on days 2 and 3
Study: 21063118
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg once daily for 3-6 weeks before cardioversion and 16 mg once daily for 6 months after cardioversion
Study: 15522993
Drug: Lipid +
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid + heparin emulsion
Study: 11823085
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of ARBs and ACEIs
Study: 2678858
Drug: Short-term antibiotic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term antibiotic prophylaxis (cefotaxime for biliary or gastric, gentamicin/metronidazole for colorectal)
Study: 2678858
Drug: Long-term antibiotic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antibiotic prophylaxis (cefotaxime for biliary or gastric, gentamicin/metronidazole for colorectal)
Study: 1093498
Drug: Pentaeritritol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaeritritol administered for 4 weeks
Study: 30772849
Drug: Anakinra in
Normalized name: anakinra Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra in addition to intravenous corticosteroid treatment
Study: 30772849
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to intravenous corticosteroid treatment
Study: 23376004
Drug: LBTM (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBTM (lansoprazole 30 mg twice daily, bismuth potassium citrate 220 mg twice daily, tetracycline 500 mg 4 times daily, metronidazole 400 mg 4 times daily)
Study: 23376004
Drug: LBTF (tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBTF (tetracycline 500 mg 3 times daily, furazolidone 100 mg 3 times daily)
Study: 23376004
Drug: LBAT (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBAT (amoxicillin 1000 mg 3 times daily, tetracycline 500 mg 4 times daily)
Study: 23376004
Drug: LBAF (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBAF (amoxicillin 1000 mg 3 times daily, furazolidone 100 mg 3 times daily)
Study: 19709060
Drug: Moderately rough
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately rough (tioblasted) titanium implants
Study: 19709060
Drug: Both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implant surfaces (tioblasted and turned)
Study: 15154857
Drug: Chronic daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic daily headache
Study: 15154857
Drug: Common analgesic
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common analgesic use
Study: 11866419
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (20 minutes of preselected music)
Study: 9516221
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metformin and Troglitazone
Study: 7750809
Drug: Levodopa methyl
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa methyl ester (LDME) 250 mg
Study: 18165594
Drug: Epinephrine 4
Normalized name: EPINEPHrine 4 MG in 250 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 4 microg/mL added to ropivacaine 1.8 mg/mL and fentanyl 3 microg/mL (group RFE)
Study: 18165594
Drug: Ropivacaine 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1.8 mg/mL and fentanyl 3 microg/mL without epinephrine (group RF)
Study: 9326900
Drug: Mandibular long-bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular long-bar overdenture supported by 4 implants
Study: 9326900
Drug: Two-implant hybrid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant hybrid overdenture
Study: 8472518
Drug: ST-679 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST-679 (1200 mg per day)
Study: 8472518
Drug: Tolmetin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolmetin (1200 mg per day)
Study: 24394884
Drug: Intravenous dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexketoprofen (50 mg)
Study: 24455735
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1000 mg)
Study: 10513351
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (200 micrograms/dose q.i.d.)
Study: 10513351
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 micrograms/dose q.i.d.)
Study: 7561195
Drug: Peru-15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 vaccine (2 x 10^8 cfu)
Study: 2324896
Drug: L-ascorbic acid
Normalized name: L-ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-ascorbic acid (AA) 284 mumol (50 mg) twice daily
Study: 28267011
Drug: Oral sulfate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfate solution
Study: 19584830
Drug: Oral sulfate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfate solution (split-dose)
Study: 19584830
Drug: Oral sulfate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfate solution (1-day preparation)
Study: 19584830
Drug: PEG‐EA (1-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐EA (1-day preparation)
Study: 19584830
Drug: Oral sulfate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfate solution and PEG‐EA
Study: 15136366
Drug: Rofecoxib, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib, 25 mg/d plus aspirin 100 mg/d
Study: 15136366
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin 100 mg/d
Study: 11295882
Drug: Fluctuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluctuation of blood Phe values during treatment
Study: 18476202
Drug: Electrocautery subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrocautery subcutaneous incision
Study: 18476202
Drug: Scalpel subcutaneous
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scalpel subcutaneous incision
Study: 29154073
Drug: Aqueous extract
Normalized name: green tea aqueous extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous extract of edible dried fig fruit applied twice a day for two weeks
Study: 29154073
Drug: Hydrocortisone 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 1.0% applied twice a day for two weeks
Study: 29154073
Drug: Base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base cream (placebo) applied twice a day for two weeks
Study: 23889837
Drug: Intensive Treatment
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Treatment (IT): 100 hours of speech and language therapy (2 hours per day, 5 days per week for 10 weeks)